CD274 and neoplasm: Although TNBC has a higher rate of PD-L1 expression associated with the presence of tumor-infiltrating lymphocytes, and a higher degree of mutational burden compared with other subtypes of breast cancer4–8, the overall response rate to PD-1/PD-L1 blockade therapy is still low13.